2023 Product Recalls

5,383 recalls issued in 2023.

5,383
Total Recalls
1,252
FDA Drug
89
USDA
324
CPSC
FDA Drug 1,252 USDA 89 CPSC 324 FDA Device 569 NHTSA 996 FDA Food 2,153

Showing 5381–5383 of 5,383 recalls

FDA

Argyle UVC Insertion Tray containing Safety Scalpel N11 (vendor part number 73-1811). Intended for use to insert an Umbilical Venous Catheter (UVC) into the umbilical artery or vein of neonate. Product Code: 43201

The current Argyle UVC Insertion Tray does not include a specific IFU to operate the Safety Scalpel N11. The Safety Scalpel N11 features a permanent locking feature that will not allow the clinician to unlock the scalpel once the safety shield is closed and pushed forward into a locked position may result in a delay treatment/therapy, which could ultimately result in death.

Cardinal Health issued Urgent Medical Device Correction letter and Acknowledgement Form on June 16, 2021 to the direct consignees. Letter states reason for recall, health risk and action to take: Actions Required: 1) REVIEW the IFU for the Safety Scalpel N11 (vendor part number 73-1811). 2) COMMUNICATE the IFU to all personnel that utilize the Argyle" UVC Insertion Tray (SKU 43201) containing Safety Scalpel N11 (vendor part number 73-1811) 3) NOTIFY any customers to whom you may have distributed/forwarded affected product or will send the product about this product correction notice and share a copy of this notice and the attached IFU. 4) POST a copy of this notification in the location where the product is stored. 5) RETURN the enclosed acknowledgment form via fax to 614-652-9648 or email to GMB-FieldCorrectiveAction@cardinalhealth.com whether or not you have affected product. Available Assistance: Please contact the Customer Service group for any questions or to arrange for credit and return of any product: " Hospital 800-964-5227 " Federal Government 800-444-1166 " Distributor 800-635-6021 " All other customers 888-444-5440 For questions related to the notification and/or acknowledgement form that are not adequately addressed in this letter, please contact the market action team at: GMB-FieldCorrectiveAction@cardinalhealth.com or call 800-292-9332.

FDA

Disposable Insulin Syringe 0.3mL in 3 different sizes 29Gx1/2, 30Gx5/16, and 31G x 5/16. (10 syringes are packaged in a flexible plastic (poly bag) and 10 flexible plastic (poly bag) are packaged in one in box. Finally, pack the inboxes in the carton case.)

Defect consists of a small crack in the top end of the barrel near the needle.

The company has been requesting that the importers immediately cease all distribution of affected Lot Numbers and notify its customers to do the same. The customers shall include wholesale distributors, retail pharmacies and mail order pharmacies or patients. The customer who received the affected products shall quarantine. The customers may return the affected products and the company will replace. Any and all questions pertaining to the recall and disposition of recalled product can be addressed to Yushin Kim, CEO ShinChang Medical Co.,Ltd. By email at yushin0229@scmedical.co.kr or by phone at +82-54-463-2400

FDA

MicroScan Pos MIC Panel Type 34 - Product Usage: For the determination of antimicrobial agent susceptibility and/or identification to the species level of rapidly growing aerobic and facultative gram-positive cocci, some fastidious aerobic cocci and listeria monocytogenes.

Due to a customer report and internal investigation, it was confirmed that a portion of the affected product lot failed quality control (QC) for ATCC E. Faecalis 29212 versus daptomycin and it is a possibility to obtain false elevated MIC for clinical isolates with daptomycin even when quality control results are within specification.

During the week of 12/01/2020, the Recalling Firm is sending an "URGENT MEDICAL DEVICE RECALL" Letter via e-mail and/or mail to customers informing them that due to a customer report and internal investigation, it was confirmed that a portion of the affected product lot failed quality control (QC) for ATCC E. Faecalis 29212 versus daptomycin and it is a possibility to obtain false elevated MIC for clinical isolates with daptomycin even when quality control results are within specification. Customer are instructed to: 1. Discontinue use and discard, per their laboratory procedure/guidelines, any remaining inventory of the affected lot. 2. The laboratory should consider reviewing and confirming organism identification and antimicrobial susceptibility test results of stains yielding results suggestive of a daptomycin "non-susceptible" category. 3. They should retain their inventory of other B1017-216 panel lots as they are not impacted by this issue. 4. Share this information with their laboratory staff and retain the notification as part of their laboratory Quality System documentation. If they have forwarded any of the affected product to any additional laboratories, they are instructed to provide the information/notification. 5. To assure receipt of the notification/important communication, customers are instructed to respond within 10 days in one of the following ways: -Electronically, if they received the communication via email -Manually complete and return the enclosed Response Form. The Recalling Firm is investigating the root cause of the issues and appropriate actions to prevent recurrence will be implemented. For questions, contact Customer Support Center at: -websited http://www.beckmancoulter.com -Phone 1-800-677-7226 in the United States -For customers in the United States, if replacement product is needed: --Complete the attached "Replacement Order Form" and email to askbeckman@ Beckman.com or fax to 866-294-7850 --Call Client Servic